PHarmaceutical tech@2x
  • News

    Most Read

    • Turn Therapeutics gets authorisation for Covid-19 therapeutic candidate trial
    • UAE approves Sputnik V Covid-19 vaccine for emergency use
    • Fire at Serum Institute of India facility kills five people

    Most Recent

    Drug Development

    Turn Therapeutics gets authorisation for Covid-19 therapeutic candidate trial

    22 Jan 2021
  • Analysis

    Sections

    • Features
    • Comment
    • Projects

    Most Read

    • Tackling the ‘silent pandemic’ of AMR: WHO launches the Global Leaders Group
    • Lilly drug prevents Covid infections in long-term care facilities – leading macroeconomic influencers
    • PTF: Spotting new Covid-19 variants with genome mapping

    Most Recent

    Infectious Diseases

    Tackling the ‘silent pandemic’ of AMR: WHO launches the Global Leaders Group

    22 Jan 2021
  • Sectors

    Sections

    • Clinical Trials
    • Supply Chain
    • Drug Development
    • Manufacturing
    • Diseases
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Diseases
      • Oncology
      • Respiratory

    Most Read

    • Turn Therapeutics gets authorisation for Covid-19 therapeutic candidate trial
    • Coronavirus company news summary – Moderna works with Takeda on Japan vaccine trial – Sputnik V authorised for use in the UAE
    • Tackling the ‘silent pandemic’ of AMR: WHO launches the Global Leaders Group

    Most Recent

    Drug Development

    Turn Therapeutics gets authorisation for Covid-19 therapeutic candidate trial

    22 Jan 2021
  • Themes
  • Deals

    Most Read

    • Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership
    • Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m
    • NewAmsterdam Pharma raises $196m through Series A funding round

    Most Recent

    Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership

    19 Jan 2021
  • Companies

    Sections

    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos

    Most Read

    • TOTE® SYSTEMS
    • RSD
    • Kiskun Meridian

    Most Recent

    Manufacturing

    TOTE® SYSTEMS

    20 Jan 2021
  • Magazine
  • Events
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Supply Chain
    • Drug Development
    • Manufacturing
    • Diseases
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Diseases
      • Oncology
  • Deals
  • US Election
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Powder Handling
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Reports
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register

Herantis Pharma to develop non-invasive CDNF for Parkinson’s

Finnish drug development firm Herantis Pharma has launched a new programme for the development of...

9 July 2018

Latest News

Drug Development

Turn Therapeutics gets authorisation for Covid-19 therapeutic candidate trial

22 Jan 2021
Regulation

UAE approves Sputnik V Covid-19 vaccine for emergency use

22 Jan 2021
Manufacturing

Fire at Serum Institute of India facility kills five people

21 Jan 2021
Drug Development

Akron Biotech, Octapharma enter Human AB Serum global production deal

21 Jan 2021

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
logo-horizontal

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms & Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more